ArticleFrontiers in medicine2025
The role of serum biomarkers in the decline of cognitive function in hemodialysis patients: a single-center retrospective study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cognitive impairment in hemodialysis patients is higher than that in healthy individuals. However, the potential pathogenesis is not fully clear. Methods: In this retrospective study, 48 maintenance hemodialysis (MHD) patients of our center who participated in cognitive level test 4 years ago were screened by Montreal Cognitive Assessment (MoCA). We then analyzed relationships between the MoCA-derived cognitive level score, demographic, clinical, and laboratory variables. Results: The age, dialysis age, Body Mass Index (BMI), and blood calcium levels of MHD patients were significantly abnormal than 4 years ago in this study. Furthermore, we observed that the levels of fibroblast growth factor (FGF-23) in MHD patients with cognitive decline were significantly higher than those in the normal cognitive group. Receiver operating characteristic (ROC) curves demonstrated that FGF-23 was a potential biomarker for diagnosing cognitive decline in hemodialysis patients. Conclusion: We speculate that dialysis age, increased BMI, decreased blood calcium, and the abnormal level of FGF-23 may be independent risk factors for cognitive impairment in hemodialysis patients. Moreover, BMI and decreased blood calcium can be used as predictive factors of hemodialysis-related cognitive impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.